SCHEMBL24915359

SCHEMBL24915359

O=c1c(CO)cccn1C1CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.38
KDM5A P29375 1/20 0.38
IDH1 O75874 1/20 0.38
OPRM1 P35372 1/20 0.37
OPRL1 P41146 1/20 0.37
DHODH Q02127 3/20 0.37
VEGFA P15692 1/20 0.37
EGLN1 Q9GZT9 1/20 0.37
SLC5A2 P31639 1/20 0.35
P2RX7 Q99572 1/20 0.34
DRD2 P14416 2/20 0.34
DRD4 P21917 2/20 0.34
DRD3 P35462 2/20 0.34
EPHX1 P07099 1/20 0.34
GLA P06280 1/20 0.34
POLB P06746 1/20 0.34
CHRM2 P08172 1/20 0.33
CHRM4 P08173 1/20 0.33
CHRM5 P08912 1/20 0.33
CHRM1 P11229 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21659038 0.89 TYK2 (0.36) KDM5ADHODHVEGFAEGLN1SLC5A2
SCHEMBL21659050 0.83 TYK2 (0.39) KDM5ASLC5A2P2RX7
SCHEMBL21658764 0.82 KDM5A (0.38) LMNAKDM5AIDH1OPRM1OPRL1
SCHEMBL21659043 0.81 KDM5A (0.34) KDM5AIDH1OPRM1OPRL1DHODH
SCHEMBL23120487 0.77 SMN1; SMN2 (0.57) LMNAMEN1KMT2A
SCHEMBL1857401 0.76 LMNA (0.43) LMNAIDH1DHODHVEGFAEGLN1
SCHEMBL21658766 0.74 KAT2B (0.42) LMNAKDM5AIDH1DHODHDRD2
SCHEMBL16651267 0.72 KDM5A (0.44) LMNAKDM5AIDH1DHODH
SCHEMBL30912557 0.72 DHODH (0.40) LMNAIDH1DHODHDRD2DRD4
SCHEMBL16794667 0.72 DHODH (0.40) LMNAIDH1DHODHDRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230145793-A1 SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-05-11 US disclosed
US-20230145793-A1 SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) 2023-05-11 US disclosed
EP-4122927-A1 SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) 2023-01-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230145793-A1 SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF ADORA2A, ADORA2B, ADORA3 LMNA 3817/4885KDM5A 2899/4885IDH1 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.